

Redpoint Bio CORP  
Form SC 13D/A  
March 16, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934  
(Amendment No. 1 )\***

Redpoint Bio Corporation(1)

(Name of Issuer)

Common Stock, No Par Value

(Title of Class of Securities)

09060J106

(CUSIP Number)

William J. Mosher, GlaxoSmithKline

One Franklin Plaza

P.O. Box 7929, FP2355

Philadelphia, PA 19101

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

March 12, 2010

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09060J106

NAMES OF REPORTING PERSONS.

1. GlaxoSmithKline plc

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2. (a)   
(b)

SEC USE ONLY

3.

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4. 5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  6. CITIZENSHIP OR PLACE OF ORGANIZATION England and Wales 7. SOLE VOTING POWER NUMBER OF 7,455,689 SHARES 8. SHARED VOTING POWER BENEFICIALLY OWNED BY 0 EACH 9. SOLE DISPOSITIVE POWER REPORTING PERSON 7,455,689 WITH 10. SHARED DISPOSITIVE POWER 0 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,455,689 (2) (3) 12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.3%(4) 14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO
-

Schedule 13D/A Continued

**CUSIP No. 09060J106**

**ITEM 2. Identity and Background**

The citizenship of each officer and director of GlaxoSmithKline plc is set forth in Schedule 1.

**Footnotes:**

- (1) Redpoint Bio Corporation was formerly known as Robcor Properties, Inc.
  - (2) Shares held of record by S.R. One, Limited, a wholly owned subsidiary of the Reporting Person issued as of March 12, 2010
  - (3) Warrant held of record by S.R. One, Limited, a wholly owned subsidiary of the Reporting Person, expired as of March 12, 2010
  - (4) Based on 79,838,693 shares of Common Stock as of March 12, 2010
-

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 16, 2010

By: GlaxoSmithKline plc

By: /s/ Victoria Whyte  
Name: Victoria Whyte  
Title: Deputy Company Secretary

---

## SCHEDULE 1

| Name                      | Business Address  | Principal Occupation or Employment                    | Citizenship |
|---------------------------|---|---|-------------|
| <b>Board of Directors</b> |   |   |             |
| Andrew Witty              | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Chief Executive Officer                               | British     |
| Julian Heslop             | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Chief Financial Officer                               | British     |
| Dr. Moncef Slaoui         | 709 Swedeland Road<br>King of Prussia, PA<br>19046                | Executive Director<br>Chairman Research & Development | Belgian     |
| Sir Christopher Gent      | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director                                      | British     |
| Dr. Stephanie Burns       | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director                                      | USA         |
| Lawrence Culp             | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director                                      | USA         |
| Sir Crispin Davis         | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director                                      | British     |
| Sir Deryck Maughan        | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director                                      | British     |
| Dr. Daniel Podolsky       | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director                                      | USA         |

Edgar Filing: Redpoint Bio CORP - Form SC 13D/A

|                  |   |                  |         |
|------------------|---|------------------|---------|
| Mr James Murdoch | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director | British |
| Tom de Swaan     | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Company Director | Dutch   |

---

Edgar Filing: Redpoint Bio CORP - Form SC 13D/A

| Name                            | Business Address  | Principal Occupation or Employment              | Citizenship |
|---------------------------------|---|---|-------------|
| Sir Robert Wilson               | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS         | Company Director                                | British     |
| Professor Sir Roy Anderson      | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS         | Company Director                                | British     |
| <b>Corporate Executive Team</b> |   |   |             |
| Andrew Witty                    | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS         | Chief Executive Officer                         | British     |
| Julian Heslop                   | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS         | Chief Financial Officer                         | British     |
| Daniel Troy                     | One Franklin Plaza<br>Philadelphia, PA<br>19102                           | Senior Vice President & General Counsel         | USA         |
| John Clarke                     | One Franklin Plaza<br>Philadelphia, PA<br>19102                           | President Consumer Healthcare                   | New Zealand |
| Marc Dunoyer                    | GSK Building<br>6-15, Sendagaya<br>4 chome, Shibuya-ku,<br>Tokyo 151-8566 | President<br>Asia Pacific / Japan               | French      |
| Abbas Hussain                   | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS         | President, Emerging Markets                     | British     |
| Duncan Learmouth                | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS         | Senior Vice President,<br>Global Communications | British     |

Edgar Filing: Redpoint Bio CORP - Form SC 13D/A

|                  |   |   |         |
|------------------|---|---|---------|
| William Louv     | One Franklin Plaza<br>Philadelphia, PA<br>19102                   | Chief Information Officer                 | USA     |
| Daniel J. Phelan | One Franklin Plaza<br>Philadelphia, PA<br>19102                   | Chief of Staff                            | USA     |
| Claire Thomas    | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS | Senior Vice President,<br>Human Resources | British |

---



Edgar Filing: Redpoint Bio CORP - Form SC 13D/A

| Name              | Business Address   | Principal Occupation or Employment                               | Citizenship |
|-------------------|--|--|-------------|
| David Pulman      | Five Moore Drive<br>PO Box 13398<br>Research Triangle Park<br>North Carolina 27709 | President,<br>Global Manufacturing & Supply                      | British     |
| Dr. Moncef Slaoui | 709 Swedeland Road<br>King of Prussia, PA<br>19046                                 | Executive Director<br>Chairman, Research and<br>Development      | Belgian     |
| David Redfern     | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS                  | Chief Strategy Officer   | British     |
| Jean Stéphane     | Rue de l Institut 89<br>B-1330 Rixensart<br>Belgium                                | Chairman, President and General<br>Manager,<br>Biologicals       | Belgian     |
| Edward Gray       | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS                  | President,<br>Pharmaceuticals Europe                             | British     |
| Simon Bicknell    | 980 Great West Road<br>Brentford<br>Middlesex, England<br>TW8 9GS                  | Senior Vice President, Company<br>Secretary & Compliance Officer | British     |
| Deirdre Connolly  | Five Moore Drive<br>PO Box 13398<br>Research Triangle Park<br>North Carolina 27709 | President,<br>Pharmaceuticals, North America                     | USA         |